arrow
S

Saar Gill

University of Pennsylvania
H指数:59
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Single-day non-activated IL-18-armed CAR T-cells establish a durable, stem-like state with enhanced persistence

单日未激活的IL-18武装CAR T细胞建立一种持久的、干细胞样状态并增强持久性

Blood
IF23.1
2026-04-200
PRE
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer

泛血液学癌症对嵌合抗原受体 (CAR) T细胞治疗反应的预测生物标志物

2026-03-090
PRE
Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T-cells.

抗原特异性B细胞清除在磷脂酶A2受体膜性肾病中的临床前评估,采用嵌合自体抗体受体T细胞。

2025-10-310
PRE
Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models (vol 16, 706, 2025)

嵌合抗原受体巨噬细胞(CAR-M)在预临床模型中使HER2+实体瘤对PD1阻断敏感(卷16,706,2025)

2025-03-192
OA
Evolving racial/ethnic disparities in AML survival in the novel therapy era

新型疗法时代急性髓系白血病(AML)生存率的种族/族裔差异演变

2025-01-311
PRE
Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy

经嵌合抗原受体修饰的T细胞治疗的大b细胞淋巴瘤患者免疫效应细胞相关神经毒性综合征后神经系统症状延长

2025-01-010
PRE
Cytokine-mediated CAR T therapy resistance in AML

细胞因子介导的AML car-t治疗耐药

2024-09-272
PRE
ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified fi ed Cell Therapies
2024-08-012
PRE
Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome

靶向小胶质细胞中tgf β 活化激酶-1活化可降低CAR T免疫效应细胞相关神经毒性综合征

2024-05-133
PRE
Translational insights from a phase 1, first-in-human (FIH) clinical trial of the anti-HER2 CAR macrophage CT-0508 in participants with HER2 positive metastatic breast cancer and other HER2 overexpressing solid tumors
2024-05-021
PRE
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia
2024-04-181
OAAI
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients
2024-04-015
OAAI